MyMD Pharmaceuticals Inc. [NASDAQ: MYMD] gained 10.92% on the last trading session, reaching $4.47 price per share at the time. The company report on April 28, 2021 that Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit.
Poster presentation to address the preclinical cannabidiol derivative for the potential treatment of psychiatric disorders.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced that researchers from the Johns Hopkins University School of Medicine will present the results of new research on the company’s compound Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit. The poster presentation will discuss the preclinical cannabidiol (CBD) derivative that targets endogenous cannabinoid receptor type 2 for the treatment of psychiatric disorders. The researchers studied the compound in depression and anxiety-related phenotypes in mice.
MyMD Pharmaceuticals Inc. represents 6.54 million in outstanding shares, while the company has a total market value of $179.11 million with the latest information. MYMD stock price has been found in the range of $3.94 to $4.68.
If compared to the average trading volume of 633.67K shares, MYMD reached a trading volume of 1097181 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about MyMD Pharmaceuticals Inc. [MYMD]:
The Average True Range (ATR) for MyMD Pharmaceuticals Inc. is set at 0.82 The Price to Book ratio for the last quarter was 0.85, with the Price to Cash per share for the same quarter was set at 0.88.
Trading performance analysis for MYMD stock
MyMD Pharmaceuticals Inc. [MYMD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.61. With this latest performance, MYMD shares dropped by -27.20% in over the last four-week period, additionally plugging by 2.05% over the last 6 months – not to mention a drop of -39.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MYMD stock in for the last two-week period is set at 38.81, with the RSI for the last a single of trading hit 38.34, and the three-weeks RSI is set at 40.84 for MyMD Pharmaceuticals Inc. [MYMD]. The present Moving Average for the last 50 days of trading for this stock 6.18, while it was recorded at 4.23 for the last single week of trading, and 5.96 for the last 200 days.
MyMD Pharmaceuticals Inc. [MYMD]: A deeper dive into fundamental analysis
MyMD Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 16.30.
An analysis of insider ownership at MyMD Pharmaceuticals Inc. [MYMD]
There are presently around $2 million, or 3.00% of MYMD stock, in the hands of institutional investors. The top three institutional holders of MYMD stocks are: NORTHROCK PARTNERS, LLC with ownership of 212,500, which is approximately New of the company’s market cap and around 0.20% of the total institutional ownership; ANSON FUNDS MANAGEMENT LP, holding 135,135 shares of the stock with an approximate value of $0.6 million in MYMD stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $0.22 million in MYMD stock with ownership of nearly New of the company’s market capitalization.
9 institutional holders increased their position in MyMD Pharmaceuticals Inc. [NASDAQ:MYMD] by around 459,553 shares. Additionally, 6 investors decreased positions by around 158,758 shares, while 6 investors held positions by with 82,460 shares. The mentioned changes placed institutional holdings at 535,851 shares, according to the latest SEC report filing. MYMD stock had 6 new institutional investments in for a total of 437,077 shares, while 2 institutional investors sold positions of 150,107 shares during the same period.